主页 > 医学讨论 >
【medical-news】脑瘤疫苗有好实验结果
Brain Tumor Vaccine Has Promising Results
U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.
Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.
The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.
Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.
"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.
The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology. 本人已经认领此文. 如在48小时内未能提交译文, 其他战友可自由认领. Brain Tumor Vaccine Has Promising Results
脑瘤疫苗研究结果有很好的前景
U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.
美国肿瘤研究专家称针对复发神经胶质瘤的疫苗在临床初期试验中显示很好的结果。
Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.
加利福尼亚大学旧金山脑瘤研究中心的专家们将患者自身肿瘤制备的疫苗-vitespen（商品名Oncophage）在第一组共六个病人身上进行试验。
The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.
研究结果初步显示疫苗可使复发的恶性胶质瘤患者产生肿瘤特异性免疫反应。
Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.
神经胶质瘤是来源于在神经细胞周围起支持作用的胶质细胞的一种原发肿瘤。脑是最常见的发病部位。目前恶性胶质瘤是致命疾病。
"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.
加利福尼亚旧金山神经外科副教授和此项研究的主要参与者Andrew Parsa教授认为这是首次报道关于vitepen免疫患者后能产生胶质瘤特异的免疫反应。基于初期的临床试验结果，2007年将计划进行更大范围的II期临床试验。
The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology.
上周在加利福尼亚的奥兰多举行的由神经肿瘤学学会举办的会议上公布了这一临床试验结果。 脑瘤疫苗研究结果有很好的前景
美国肿瘤研究专家称针对复发神经胶质瘤的疫苗在临床初期试验中显示很好的结果。这一结果是上周在加利福尼亚奥兰多的神经肿瘤学学会举办的会议上公布的。神经胶质瘤是来源于在神经细胞周围起支持作用的胶质细胞的一种原发肿瘤。脑是最常见的发病部位。目前恶性胶质瘤是致命疾病。加利福尼亚大学旧金山脑瘤研究中心的专家们将患者自身肿瘤制备的疫苗-vitespen（商品名Oncophage）在第一组共六个病人身上进行试验。研究结果初步显示疫苗可使复发的恶性胶质瘤患者产生肿瘤特异性免疫反应。加利福尼亚旧金山神经外科副教授和此项研究的主要参与者Andrew Parsa教授说，这是首次报道关于vitepen免疫患者后能产生胶质瘤特异的免疫反应。基于初期的临床试验结果，2007年将计划进行更大范围的II期临床试验。 Oncophage是一种个体化治疗肿瘤的肿瘤疫苗，虽然已经进行III期肾癌和黑色素瘤，但是结果并不太让人满意。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-05 17:46
医学,生命科学网